期刊文献+

NK细胞对非小细胞肺癌细胞NCI-H292的杀伤作用及对其β-catenin蛋白表达的影响 被引量:8

下载PDF
导出
摘要 目的探讨自然杀伤(NK)细胞对肺癌细胞系NCI-H292的杀伤作用及对癌细胞中β-catenin蛋白表达的影响。方法无菌采集健康人外周血,培养NK细胞(NK组),取培养14 d后的NK细胞,调整细胞浓度为5×106/m L,按1∶5的比例接种到NCI-H292细胞(NK+NCI-H292组)培养板共培养24 h,单独培养NCI-H292细胞(NCIH292组)24 h。采用CCK-8法测算NK细胞对肺癌细胞系NCI-H292的杀伤活性,采用Western blotting法检测NCIH292细胞中β-catenin蛋白的表达。结果 NK细胞对NCI-H292细胞的杀伤率为96.720%±1.081%,与NK及NCI-H292组比较,NK+NCI-H292组β-catenin表达降低(P均<0.01)。结论 NK细胞对NCI-H292细胞具有杀伤力,同时能够抑制NCI-H292细胞中β-catenin蛋白的表达。
出处 《山东医药》 CAS 北大核心 2017年第45期33-35,共3页 Shandong Medical Journal
基金 河北省省级重大医学研究课题(ZD2013063)
  • 相关文献

参考文献2

二级参考文献16

  • 1Mendrola JM, Berger MB, King MC, et al. The single transmembrane do- mains of ErbB receptors self-associate in cell membranes [ J ]. J Biol Chem, 2002,277 ( 7 ) :4704-4712.
  • 2Novello S, Kie|horn A, Stynes G, et al. Cost-minimisation analysis compa- ring gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy [ J ]. Lung Cancer,2005,48 ( 3 ) :379-387.
  • 3WHO handbook for reporting results of cancer treatment [ M ]. Offset Publi- cation No. 48. Geneva (Switzerland) :World Health Organization, 1979.
  • 4Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, et al. Randomized phase II stud- y of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy [ J ]. Lung Cancer, 2012,75 : 82- 88.
  • 5Junshik Hong, Sun Young Kyung, Sang Pyo Lee, et al. Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer[ J]. Original Article, 2010,25 (3) :294-300.
  • 6Sun Y, ShiY,Zhang L, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (nselc) previously treated with chemotherapy (icogen)[ J ]. J Clin Oncol, 2011,29(Suppl) : abstr 7522.
  • 7Thatcher N, Chang A, Parikhp P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung canc- er : results from a randomised, placebo-controlled, muhicenter study ( iressa survival evaluation in lung cancer) [ J ]. Lancet, 2005,366 (9496) : 1527- 1537.
  • 8Wells GA, Sultan SA, Chen L, et ah Indirect treatment comparison [ com- puter program]. Version 1.0. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009.
  • 9张晓庆,李玉平,倪健,刘皋林.吉非替尼与厄洛替尼治疗非小细胞肺癌疗效及药物经济学评价[J].中国新药与临床杂志,2009,28(11):837-840. 被引量:12
  • 10王治华,唐勇,曲彦丽,单利,赛福丁.吉非替尼与厄罗替尼治疗晚期非小细胞肺癌的临床分析[J].实用肿瘤杂志,2010,25(2):195-199. 被引量:5

共引文献52

同被引文献83

引证文献8

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部